StockTake: Neurizon’s lead asset shows positive results in latest study
StockTake
share
Neurizon Therapeutics’ (ASX:NUZ) lead drug candidate has demonstrated positive results in the latest round of testing with Tessara Therapeutics.
NUZ-001 has shown it promotes healthy and viable brain tissues, potentially demonstrating its use to provide short-term treatment for further neurodegenerative diseases.
Watch the video to hear more.
This video was developed in collaboration with Neurizon Therapeutics, a Stockhead advertiser at the time of publishing.
This video does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.
